OU will expand the nationally recognized Stephenson Cancer Center research ecosystem with focus on reducing incidence, improving early detection, and delivering more effective, personalized therapies for cancers that disproportionately affect Oklahomans.
This effort will strengthen OU’s ability to translate discovery into clinical benefit while addressing disparities in cancer outcomes across rural, Tribal, and underserved communities.
Stephenson Cancer Center serves as a major source of biomedical discovery into the nature of cancer and for the development of new and more effective treatments. It's 130 member investigators are currently working on more than 400 cancer research projects, supported by $65 million of annual research funding from the National Institutes of Health, American Cancer Society and others. This team has published more than 1450 scientific articles over the past five years, advancing science and influencing how patients are treated in Oklahoma and around the world.
More than 250 researchers, clinicians, engineers, entrepreneurs and students gathered Sept. 25 for the University of Oklahoma’s first Cross-Campus Translational Biomedical Research Symposium.
A University of Oklahoma physician-researcher recently received $2.9 million in funding from the National Cancer Institute to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.
Research published today in Cell identifies three small subclusters of cells driving pancreatic cancer-induced cachexia, a muscle-wasting and fat-loss condition that makes patients less tolerant of cancer treatment. The study, led by the University of Oklahoma, holds significant promise for the development of therapeutics to target these subclusters.
New research from the University of Oklahoma, published in Cell Death & Differentiation, demonstrates how an aggressive form of breast cancer co-opts the body’s own immune system to attract nerves that fuel tumor growth.
The TSET Health Promotion Research Center (HPRC) within the National Cancer Institute-Designated OU Health Stephenson Cancer Center at the University of Oklahoma Health Campus (OUHC) has awarded four FY27 seed grants to support innovative research aimed at improving the health of Oklahomans.
The University of Oklahoma College of Medicine has named Kelly Stratton, M.D., FACS as associate dean for veterans affairs, pending approval by the OU Board of Regents.
The Oklahoma Tobacco Settlement Endowment Trust (TSET) has awarded the University of Oklahoma a $25 million grant to help construct a new OU Health Stephenson Cancer Center facility in Tulsa, a project that will house the newly named TSET Clinical Research Center and significantly expand access to clinical trials and cancer care in the region.
University of Oklahoma researcher Elizabeth Wellberg, Ph.D., is the senior author of a review article in The Journal of Clinical Investigation that gathers current research evidence about the effects of GLP-1 drugs, like Ozempic and Zepbound, on cancer risk.
OU Health Stephenson Cancer Center today celebrated the groundbreaking of its new 176,000-square-foot facility on the University of Oklahoma’s Schusterman Center campus, marking a transformative step forward in expanding access to National Cancer Institute-designated cancer care for thousands of residents in northeast Oklahoma.
The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma Health Stephenson Cancer Center.
